Preclinical prevent cancer program: preclinical efficacy and intermediate endpoint biomarkersperiod of performance: 9/22/2015 - 9/21/2018

Ended Awarded Last action

Contract number
HHSN261201500032I
Awardee
Awarding agency
Task orders
3 $1,874,857 obligated

Award facts

Combined order value
$1,874,857 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 6% used
$29,800,000.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 9 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The National Cancer Institute (NCI), part of the Department of Health and Human Services, has awarded an Indefinite Delivery Contract (IDC) valued at $29,800,000 to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The contract, titled "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS," has a period of performance from September 22, 2015 to September 21, 2018.

Under this multiple-award IDC, The Institute for Cancer Research is providing comprehensive preclinical research services to support the NCI's PREVENT Cancer Preclinical Drug Development Program. The research services span three technical areas: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. The research aims to identify pharmacodynamic and efficacy biomarkers, conduct preclinical product development, support CGMP manufacturing, and perform toxicology and pharmacology testing for potential cancer preventive agents, with a focus on chemopreventive and immunopreventive regimens. The contract does not have any set-aside designations, and the work is being performed in Philadelphia, Pennsylvania.

Task orders

Task order Ordering agency Obligated Awarded
R & D- medical: biomedical (basic research) 75N91018F00003 National Cancer Institute (NIH) $884,185
R & D- medical: biomedical (basic research) HHSN26100002 National Cancer Institute (NIH) $988,252
The research institute FO FOX chase cancer center duns: 064367329 contract orientation and kick-off meeting… HHSN26100001 National Cancer Institute (NIH) $2,420

Transactions

Action Obligated Date
Additional Work (new agreement, FAR part 6 applies) 2 · Preclinical prevent efficacy: IDIQ programmatic maximum increase $0
Other Administrative Action 1 $0
Original award $0

Quick answers

Who was awarded contract HHSN261201500032I?

HHSN261201500032I was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 22, 2015.

How much is contract HHSN261201500032I worth?

Orders under HHSN261201500032I have obligated $1,874,857. HHSN261201500032I's own ceiling is $29,800,000.

How many orders have been placed under contract HHSN261201500032I?

3 orders have been placed under HHSN261201500032I, the latest on July 25, 2018.

Who can order from contract HHSN261201500032I?

HHSN261201500032I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract HHSN261201500032I part of a contract vehicle?

Yes. HHSN261201500032I is part of PREVENT Cancer Program (PREVENT).

Was contract HHSN261201500032I competed?

The extent of competition for HHSN261201500032I was full and open competition. The government received 9 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login